Glenview Trust’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $26.8M | Buy |
192,157
+2,683
| +1% | +$376K | 0.42% | 54 |
|
|
2025
Q4 | $23.3M | Buy |
189,474
+1,748
| +0.9% | +$212K | 0.36% | 59 |
|
|
2025
Q3 | $20.8M | Buy |
187,726
+3,868
| +2% | +$440K | 0.33% | 68 |
|
|
2025
Q2 | $20.4M | Buy |
183,858
+7,359
| +4% | +$783K | 0.35% | 64 |
|
|
2025
Q1 | $19.8M | Buy |
176,499
+12,894
| +8% | +$1.33M | 0.38% | 61 |
|
|
2024
Q4 | $15.1M | Sell |
163,605
-595
| -0.4% | -$53.6K | 0.28% | 84 |
|
|
2024
Q3 | $13.8M | Sell |
164,200
-6,752
| -4% | -$515K | 0.26% | 86 |
|
|
2024
Q2 | $11.7M | Sell |
170,952
-15,116
| -8% | -$1.01M | 0.24% | 92 |
|
|
2024
Q1 | $13.6M | Buy |
186,068
+10,921
| +6% | +$840K | 0.29% | 82 |
|
|
2023
Q4 | $14.2M | Buy |
175,147
+7,808
| +5% | +$608K | 0.35% | 74 |
|
|
2023
Q3 | $12.5M | Buy |
167,339
+7,699
| +5% | +$592K | 0.35% | 76 |
|
|
2023
Q2 | $12.3M | Buy |
159,640
+3,954
| +3% | +$315K | 0.34% | 76 |
|
|
2023
Q1 | $12.9M | Buy |
155,686
+4,435
| +3% | +$367K | 0.39% | 74 |
|
|
2022
Q4 | $13M | Buy |
151,251
+7,325
| +5% | +$580K | 0.43% | 70 |
|
|
2022
Q3 | $8.88M | Buy |
143,926
+9,706
| +7% | +$612K | 0.34% | 75 |
|
|
2022
Q2 | $8.3M | Buy |
134,220
+5,258
| +4% | +$326K | 0.3% | 83 |
|
|
2022
Q1 | $7.67M | Buy |
128,962
+17,050
| +15% | +$1.09M | 0.25% | 90 |
|
|
2021
Q4 | $8.13M | Sell |
111,912
-64
| -0.1% | -$4.41K | 0.27% | 86 |
|
|
2021
Q3 | $7.82M | Buy |
111,976
+4,590
| +4% | +$322K | 0.3% | 85 |
|
|
2021
Q2 | $7.39M | Buy |
107,386
+11,231
| +12% | +$750K | 0.29% | 87 |
|
|
2021
Q1 | $6.21M | Buy |
96,155
+6,981
| +8% | +$450K | 0.27% | 90 |
|
|
2020
Q4 | $5.2M | Sell |
89,174
-39,660
| -31% | -$2.39M | 0.24% | 91 |
|
|
2020
Q3 | $8.14M | Buy |
128,834
+2,596
| +2% | +$180K | 0.42% | 70 |
|
|
2020
Q2 | $9.71M | Buy |
126,238
+16,852
| +15% | +$1.29M | 0.55% | 55 |
|
|
2020
Q1 | $8.18M | Buy |
109,386
+21,744
| +25% | +$1.5M | 0.57% | 54 |
|
|
2019
Q4 | $5.7M | Sell |
87,642
-11,188
| -11% | -$729K | 0.32% | 85 |
|
|
2019
Q3 | $6.26M | Buy |
98,830
+5,075
| +5% | +$332K | 0.38% | 78 |
|
|
2019
Q2 | $6.33M | Buy |
93,755
+4,599
| +5% | +$303K | 0.39% | 79 |
|
|
2019
Q1 | $5.8M | Buy |
89,156
+9,246
| +12% | +$615K | 0.37% | 80 |
|
|
2018
Q4 | $5M | Sell |
79,910
-9,446
| -11% | -$660K | 0.37% | 80 |
|
|
2018
Q3 | $6.9M | Buy |
89,356
+1,889
| +2% | +$143K | 0.43% | 68 |
|
|
2018
Q2 | $6.2M | Buy |
87,467
+2,944
| +3% | +$208K | 0.46% | 69 |
|
|
2018
Q1 | $6.37M | Sell |
84,523
-73
| -0.1% | -$5.8K | 0.44% | 73 |
|
|
2017
Q4 | $6.06M | Sell |
84,596
-7,682
| -8% | -$583K | 0.42% | 81 |
|
|
2017
Q3 | $7.48M | Sell |
92,278
-1,723
| -2% | -$132K | 0.55% | 63 |
|
|
2017
Q2 | $6.65M | Sell |
94,001
-29,203
| -24% | -$1.94M | 0.52% | 71 |
|
|
2017
Q1 | $8.37M | Buy |
123,204
+1,375
| +1% | +$96.7K | 0.66% | 54 |
|
|
2016
Q4 | $8.72M | Buy |
+121,829
| New | +$9.06M | 0.72% | 48 |
|
|
2015
Q4 | $12.5M | Buy |
+123,855
| New | +$12.9M | 1.3% | 24 |
|
|
2014
Q4 | $10.7M | Buy |
+114,043
| New | +$11.8M | 1.15% | 33 |
|
|
2013
Q4 | $377K | Buy |
+5,026
| New | +$350K | 0.04% | 159 |
|
Other funds holding GILD
VCM
VPM
Glenview Trust's GILD Position: Q1 2026 in Review
Glenview Trust increased its Gilead Sciences (GILD) stake by 1.4% in Q1 2026, buying an estimated $376K and bringing the position to 192,157 shares worth $26.8M. The position accounts for 0.42% of the portfolio, ranked #54.
Glenview Trust first reported a position in GILD in Q4 2013 and has held it in 41 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Glenview Trust held 192,157 shares of Gilead Sciences worth $26.8M as of Q1 2026.
- Glenview Trust bought 2,683 Gilead Sciences shares in Q1 2026, an estimated $376K.
- Gilead Sciences made up 0.42% of Glenview Trust's portfolio in Q1 2026, its #54 holding.
- Glenview Trust first reported a position in Gilead Sciences in Q4 2013 and has held it in 41 quarters since.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Glenview Trust's 13F filing for Q1 2026, filed 8 May 2026.